Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heme iron polypeptide is an oral iron supplement derived from hemoglobin. It is used to treat or prevent low levels of iron in the blood, particularly in cases of anemia due to chronic disease, pregnancy, kidney failure, or when patients cannot tolerate traditional non-heme (ferrous) oral irons. Heme iron is absorbed via a different pathway than non-heme irons and may be better tolerated with fewer gastrointestinal side effects. It is not FDA-approved as a pharmaceutical drug but is widely available as a dietary supplement and sometimes included in combination products for anemia management[1][2][3]. Its primary mechanism involves providing bioavailable elemental iron for incorporation into hemoglobin and other essential proteins involved in oxygen transport[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heme iron polypeptide.